20 articles
A small molecule called UNI418 shuts down cancer cells' DNA repair machinery, making drug-resistant tumors vulnerable to treatment again.
Scientists discover D-cysteine selectively targets cancer cells by disrupting their energy production without harming normal cells.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
Bemnifosbuvir blocks hepatitis E replication in lab tests, offering hope for treating a virus that kills 70,000 people annually.
New DoriVac platform uses folded DNA structures to trigger strong immune responses while being easier to manufacture and store than mRNA vaccines.
Researchers identify N4BP2, the enzyme behind chromothripsis - a genetic catastrophe that helps one in four cancers rapidly evolve and resist treatment.
Experimental PCAI compounds blocked over 90% of pancreatic cancer cell migration and triggered self-destruction by hyperactivating tumor growth pathways.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells — disabling it could unlock powerful new treatments.
Researchers discovered why fibrolamellar carcinoma resists immunotherapy and found an existing drug can free trapped T cells to fight it.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
Northwestern researchers dramatically boosted cancer vaccine effectiveness by simply repositioning one protein fragment on their nanovaccine.
New research reveals why BET inhibitor cancer drugs work in labs but fail in patients, pointing to better treatment strategies.
A UCLA study found that aggressive small cell cancers lacking the RB gene depend on protein E2F3 to survive — blocking it stopped tumor growth in lab models.
MYC protein doesn't just fuel tumor growth — it also repairs DNA damage from chemotherapy, revealing a key resistance mechanism.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months — reshaping treatment strategy.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
A small genetic change in bat viruses may enable them to infect humans.
